Experienced in Immunodeficiency with Hyper IgM Type 1

Dr. Akm M. Hossain

Hematology Oncology | Psychiatry | Hematology
Baycare Medical Group, Inc.
3001 W Dr Martin Luther King Jr Blvd, 
Tampa, FL 
Accepting New Patients
Offers Telehealth
Experienced in Immunodeficiency with Hyper IgM Type 1
Baycare Medical Group, Inc.
3001 W Dr Martin Luther King Jr Blvd, 
Tampa, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Akm Hossain is a Hematologist Oncology specialist and a Psychiatrist in Tampa, Florida. Dr. Hossain is rated as an Experienced provider by MediFind in the treatment of Immunodeficiency with Hyper IgM Type 1. His top areas of expertise are Childhood Iron Deficiency Anemia, Breast Cancer, Colorectal Cancer, and Non-Hodgkin Lymphoma. Dr. Hossain is currently accepting new patients.

His clinical research consists of co-authoring 5 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Psychiatry
Hematology
Licenses
Internal Medicine in WV
Hospital Affiliations
St Josephs Hospital
Winter Haven Hospital
South Florida Baptist Hospital
Languages Spoken
English
Bengali
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
AvMed
  • HMO
  • POS
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Florida Blue
  • EPO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Options
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Sunshine Health
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

BAYCARE MEDICAL GROUP, INC.
3001 W Dr Martin Luther King Jr Blvd, Tampa, FL 33607
Other Locations
BAYCARE MEDICAL GROUP, INC.
2461 Enterprise Rd, Suite C, Clearwater, FL 33763
BAYCARE MEDICAL GROUP, INC.
6901 Simmons Loop, Riverview, FL 33578
BAYCARE MEDICAL GROUP, INC.
3003 W Dr Martin Luther King Jr Blvd, Tampa, FL 33607

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Randomized, Double-Blind, Placebo-Controlled Pilot Study of an Oral, Selective Peripheral Opioid Receptor Antagonist in Advanced Non-Small Cell Lung Cancer
A Randomized, Double-Blind, Placebo-Controlled Pilot Study of an Oral, Selective Peripheral Opioid Receptor Antagonist in Advanced Non-Small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: July 17, 2025
Intervention Type: Other, Drug
Study Drug: Naloxegol
Study Phase: Phase 2
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)
Enrollment Status: Active_not_recruiting
Publish Date: March 30, 2025
Intervention Type: Drug
Study Phase: Phase 3
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Other
Study Phase: Phase 3
A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First- or Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer
A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First- or Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer
Enrollment Status: Suspended
Publish Date: August 20, 2024
Intervention Type: Other, Drug
Study Phase: Phase 3
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 03, 2024
Intervention Type: Drug, Other
Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Paclitaxel
Study Phase: Phase 3
View 4 Less Clinical Trials

4 Total Publications

A dynamic prediction engine to prevent chemotherapy-induced nausea and vomiting.
A dynamic prediction engine to prevent chemotherapy-induced nausea and vomiting.
Journal: Artificial intelligence in medicine
Published: April 20, 2018
Similar Doctors
Experienced in Immunodeficiency with Hyper IgM Type 1
Dr. Wenqing Zhang
Hematology | Hematology Oncology | Oncology
Experienced in Immunodeficiency with Hyper IgM Type 1
Dr. Wenqing Zhang
Hematology | Hematology Oncology | Oncology

Florida Cancer Specialists And Research Institute, LLC

521 N Lecanto Hwy, Florida Cancer Specialists, 
Lecanto, FL 
 (61.3 miles away)
352-746-0707
Languages Spoken:
English, Mandarin
See accepted insurances
Accepting New Patients
Offers Telehealth

Wenqing Zhang is a Hematologist and a Hematologist Oncology provider in Lecanto, Florida. Dr. Zhang is rated as an Advanced provider by MediFind in the treatment of Immunodeficiency with Hyper IgM Type 1. His top areas of expertise are Human Monocytic Ehrlichiosis, Lung Cancer, Iron Deficiency Anemia, Childhood Iron Deficiency Anemia, and Bone Marrow Aspiration. Dr. Zhang is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hossain's expertise for a condition
ConditionClose
    View All 10 Advanced Conditions
    View All 85 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile